Neurotech Investor Presentation

Perth, Australia & Malta – 4 October 2017 – Neurotech International Limited (ASX: NTI) (“Neurotech” or the “Company”), developer of quality medical solutions in the neuroscience space, is pleased to attach our most recent investor presentation.

The Company has also uploaded testimonials from parents of children using the Mente Autism device, which is available at http://www.mentetech.com/mente-autism/testimonials/.

-ends-

About Neurotech

Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech’s primary mission is to improve the lives of people with neurological conditions, with a vision of becoming the global leader in home-use and clinical neurotechnology solutions that are both accessible and affordable. Through flagship device Mente Autism and its associated platform, Neurotech is focused on the development and commercialisation of technological solutions for the diagnosis and treatment of such conditions, starting with autism.

Mente Autism is a clinical-quality EEG device that uses neurofeedback technology to help children with ASD. Designed for home use, Mente Autism helps relax the minds of children on the spectrum which in turns helps them to focus better and engage positively with their environment.

For more information about Neurotech and Mente Autism please visit:


For more information please contact:

Matthew Wright
matt@nwrcommunications.com.au
Tel: +61 451 896 420
Investor Presentation
Neurotech International Limited (ASX: NTI) | October 2017

Improving the lives of people with neurological conditions
Neurotech Overview

✓ Medical device company, focussed on the development & commercialisation of regulated medical solutions for diagnosis & treatment of neurological disorders

✓ Flagship device Mente Autism provides home-based neurofeedback therapy to children on the autism spectrum

✓ Significant distributor momentum with five new agreements signed since IPO in November 2016, expanding the geographic reach of Mente Autism

✓ Continued validation of Mente Autism with outstanding preliminary results from the independent US Clinical Trial

✓ Continued focus on R&D, product improvement & increasing awareness

✓ Substantial achievements in less than 12 months, from first batch production at the end of 2016 to strong traction today

✓ Strong leadership with highly qualified board & senior management team
Capital Structure & Key Shareholders

Market Capitalisation & Enterprise Value

<table>
<thead>
<tr>
<th></th>
<th>Units</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ordinary shares</td>
<td>m</td>
<td>88.0</td>
</tr>
<tr>
<td>Options</td>
<td>m</td>
<td>10.9</td>
</tr>
<tr>
<td>Fully diluted capital1</td>
<td>m</td>
<td>98.9</td>
</tr>
<tr>
<td>Share price (as at 28 September 2017)</td>
<td>A$</td>
<td>0.260</td>
</tr>
<tr>
<td>Market capitalisation (as at 28 September 2017)</td>
<td>A$m</td>
<td>22.9</td>
</tr>
<tr>
<td>Net debt / (cash)²</td>
<td>A$m</td>
<td>(2.3)</td>
</tr>
<tr>
<td>Enterprise value</td>
<td>A$m</td>
<td>20.6</td>
</tr>
</tbody>
</table>

Substantial Shareholders

<table>
<thead>
<tr>
<th>Shareholders</th>
<th>Ordinary Shares</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Krystle Attard Trevisan</td>
<td>19.7</td>
<td>22.4%</td>
</tr>
<tr>
<td>Transcontinental Investments Pty Ltd</td>
<td>5.4</td>
<td>6.1%</td>
</tr>
<tr>
<td>Shimano Ventures Ltd</td>
<td>4.7</td>
<td>5.3%</td>
</tr>
<tr>
<td><strong>Sub-total</strong></td>
<td><strong>29.8</strong></td>
<td><strong>33.9%</strong></td>
</tr>
<tr>
<td>Other shareholders</td>
<td>58.2</td>
<td>66.1%</td>
</tr>
<tr>
<td><strong>Total shares</strong></td>
<td><strong>88.0</strong></td>
<td><strong>100.0%</strong></td>
</tr>
</tbody>
</table>

Notes:
1. Includes all 10.9m options with an exercise price of $0.20.
2. As at 30 June 2017.
Highly Experienced Board

**Peter O’Connor**  
Chairman (Non-Exec)  
MA, Barrister-at-Law  
- Deep experience in global funds management, asset allocation & manager selection advisory  
- Held senior public company directorships (UK, Canada & Australia)  
- Non-executive director of Northern Star Resources (ASX:NST)

**Peter Griffiths**  
Deputy Chairman & Non-Exec Director  
B.Sc. (Hons)  
- 20 years of senior level leadership experience in software & data analytics with CA Technologies, IBM & Cognos  
- Experience in management consulting & financial services  
- Responsible for investment & strategy across five business units at CA Technologies, driving leadership in enterprise & growth markets

**Dr Adrian Attard Trevisan**  
Founder & Non-Exec Director  
- Neuroscientist, founder of AAT Research & key developer of Mente  
- PhD in Human Physiology (Università degli Studi di Milano), Masters in Engineering & Audiological Sciences  
- Research Fellow at Bedfordshire Centre for Mental Health Research (BCMHR) in association with the University of Cambridge

**Wolfgang Storf**  
Chief Executive Officer  
- 20+ years experience in commercial, technical, operations & R&D in the pharmaceutical & medical industry, both for multinational & private businesses  
- Previous roles include CEO of Novartis-Sandoz, GM of Johnson & Johnson & other senior management positions covering Europe, Latin America, Middle East, Africa, Canada & Asia

**Simon Trevisan**  
Non-Exec Director  
B.Ec, Lib (Hons), MBT  
- 20+ years of experience in public & private investments, corporate finance & management of large public & private businesses  
- Managing Director of Transcontinental Group  
- Director of Assetowl Ltd (ASX:AO1), Zeta Petroleum (ASX:ZTA) & BMG Resources (ASX:BMG)

**Cheryl Tan**  
Non-Exec Director  
B.Sc (Hons), B.Comm  
- 10 years of experience in corporate advisory & finance industry, across wide variety of engagements including project financing, general corporate advisory & M&A  
- Associate Director at Azure Capital Ltd
Autism Spectrum Disorder (ASD)

- ASD (or autism) is a lifelong development condition
- One in 68 children have some form of ASD
- There is no cure, so the goal of every treatment is to:
  - manage or reduce symptoms
  - lower the risk of additional developmental delays
  - improve lifestyle
- Patients have difficulties in learning, social interaction, communication, restricted & repetitive interests & behaviours, & sensory sensitivities
- Estimated financial impact:
  - A$50-60,000 p.a.\(^2\) best practice management in Australia
  - US$1.4-2.4 million\(^3\) lifetime cost of autism

Standard treatments include\(^1\)

- **Behaviour & communication therapies**
  - (structure, direction & organisation for patient)
- **Educational therapies**
  - (occupational, sensory or speech therapy)
- **Medication**
  - (generic neuro-blockers, prescribed by medical practitioners)
- **Neurofeedback**
  - (EEG testing / monitoring at clinics)

Mente Autism is the first medical device to bring a highly specialised & clinical grade treatment safely & affordably into the home

Source:
1. As presented at the International Brain Stimulation Conference, March 2015
2. Study commissioned by the National Disability Insurance Scheme (to be released in 2016; “Autism experts’ alarm over NDIS problems.” the Australian, 20 Jan 16).
**Medical Neurotechnology**
- Understanding & influencing the brain & nervous system
- ‘Next frontier’ in medical science
- More than two billion people suffer from a brain / nervous system illness
- More than US$3 trillion economic burden on brain related illness
- More than US$169 billion in revenue generated by medical neurotechnology market in 2014 (5% growth rate)

**Clinical Grade Home Care**
- Health care moving toward precision-based personal care
- Particularly for lifestyle disorders & chronic disorders
- Driven by increased diagnoses & technological advances to bring hospital treatments & technologies into the home
- Increased adoption of regular monitoring to improve lifestyle & reduce medical costs
- Critical that clinician is still involved
First Target Consumer Market – Europe

United Kingdom
Population: 65 million
Target market: 32,500

Germany, Austria & Switzerland
Populations: 98 million
Target market: 49,000

Italy
Population: 61 million
Prevalence of autism: 1%
3-12 years target segment: 10% of autistic sufferers
Target market: 50% of segment, i.e. 30,500

France
Population: 66 million
Target market: 33,000

Seeking to penetrate >140k consumer market over next 24 months
Mente Platform

✓ One central analysis hub for medical professionals to diagnose & monitor patients remotely
✓ Shorter clinic queues, no waiting time
✓ Trust-building with medical professionals
✓ Less disruption for patients, with no need to go to into clinic
How Mente Autism works

1. Connect to Wi-Fi
2. Run the Mente App
3. Brainwaves are acquired
4. Mente Autism algorithms process the EEG waves & deliver auditory feedback
5. Auditory feedback consists of different binaural beats tailored on EEG activity
6. Binaural beats aims to entrain EEG activity into a desired frequency
7. Closed loop created by monitoring resulting brainwaves & then modulating soundwaves
8. Session ends automatically after 40 minutes & data uploaded to Mente Cloud
9. Session data available via user dashboard & Mente App

Resulting benefits:
- Increased relaxation
- Improved sleep
- Enhanced concentration & involvement
- Improved behaviour & social interactions
Validation

• Neurofeedback stimulation for autism management has been around since the late 1990’s

• **Over 20 medical papers** published on studies of baseload EEG profiles & brain imaging of ASD children, the efficacy of neurofeedback as a treatment form for ASD & other neurological conditions & literature reviews

• **6 studies & presentations papers** published by the Company & the Company’s founder, Dr Attard Trevisan, on Mente Autism & its foundational technologies

• **2 additional user studies conducted by the Company**, encompassing 33 patients
  Both studies showed significant improvement in the patients’ EEG profile, behavioural improvements & improved communication

• **2 independent user studies in Italy finalised**
  4-patient user study at one of Bologna, Italy’s main hospitals, Ospedale Maggiore di Bologna, commissioned by ANGSA (Italy’s main autism lobby group)
  4-patient user study, commissioned by Comitato Provincale di Roma, the Italian Red Cross

• **Over 200 current active Mente users**
  Over 50% of those classified as having undertaken a statistically significant number of sessions were determined to have experienced significant physiological & behavioural improvements

• **Double blind, independent US clinical trial conducted by the Carrick Institute is showing outstanding preliminary results**
2015 Pilot Study\(^1\)

- 25 participant study of children diagnosed with autism as undertaken to test the efficacy of a four-channel Mente system.
- In people with autism, delta waves (normally associated with sleep) are abnormally high while alpha & beta waves (normally associated with focus & mental activity) are abnormally low.
- After daily 40 minute sessions for 15 weeks the participants experienced **significantly decreased delta waves, significantly increased alpha & beta waves & noticeable behavioural improvements**\(^1\).

### Physiological Improvements

<table>
<thead>
<tr>
<th>Wave Type</th>
<th>Before</th>
<th>After</th>
</tr>
</thead>
<tbody>
<tr>
<td>Delta</td>
<td>14%</td>
<td>12%</td>
</tr>
<tr>
<td>Alpha</td>
<td>17%</td>
<td>12%</td>
</tr>
<tr>
<td>Beta</td>
<td>17%</td>
<td>17%</td>
</tr>
</tbody>
</table>

### Behavioural Improvements

<table>
<thead>
<tr>
<th>Behaviour Type</th>
<th>Before</th>
<th>After</th>
</tr>
</thead>
<tbody>
<tr>
<td>Negative attentional behaviours</td>
<td>26%</td>
<td>19%</td>
</tr>
<tr>
<td>Escape behaviour</td>
<td>23%</td>
<td>19%</td>
</tr>
<tr>
<td>Non-social behaviour</td>
<td>36%</td>
<td>36%</td>
</tr>
<tr>
<td>Negative physical symptoms</td>
<td>23%</td>
<td>23%</td>
</tr>
</tbody>
</table>

Source:  
Preliminary US Clinical Trial Outcomes

Outstanding preliminary results from US clinical study

- Positive changes in autistic children’s neurological function
- Many of the children scoring in a normal range after the treatment

“...one of the most exciting investigations this year. The changes observed in autistic children after a 12-week clinical trial are outstanding with many of the children with autism scoring in a normal range after the treatment.”

- Dr Ahmed Hankir, Senior Research Fellow with the Bedfordshire Centre for Mental Health Research (BCMHR) in association with the University of Cambridge

“The study is ongoing but half of the children in our study have completed it & we have observed major positive changes in the children in the active arm of the study & no statistical changes in the control group of children that did not receive the active treatment.”

- Professor Carrick, Senior Research Fellow at BCMHR, principal clinical trial investigator
The Mente Autism device already has European CE Marking, thus enabling sales in Europe, Middle East & Australia. The Company will seek to also obtain US FDA clearance for the device.

Current Certifications & Registrations

- CE Marking
  - Mente Autism & Mente Autism predecessor (Mente 2) both classified as a Class IIa medical device
  - Regulated under the European Union Council Medical Device Directive 93/42/EEC
- FDA
  - Mente 2 listed as a Neurological Biofeedback Medical Device classified as Class 2 (special controls) under regulation number 882.5050
  - Fully-owned Neurotech subsidiary, AAT Medical, is registered as a developer of medical devices (Registration number: 3010806606) – required for selling medical devices in the United States
- ISO 13485 Certified
  - AAT Medical is ISO 13485 certified
  - Meets specific requirements & guidelines for a quality management system, to develop & provide products & services, that consistently meet both customer & regulatory requirements
- TGA Registration
  - Mente Autism is included on the Australian Register of Therapeutic Goods as a biofeedback system in the Medical Device Class IIa category

FDA Submission Process

The Company will seek to market Mente Autism as a Class II regulated device in the US via the traditional 510(k) submission route:

- ✓ Pre-submission package filed: Mar 2017
- ✓ Pre-submission meeting: Jun 2017
- □ Final submission targeted: Q1 2018
- □ FDA clearance targeted: during 2018
Product Bundling

Complete Mente Autism Kit

Comprising headband, power supply, earphones, sensors, Quickguide, cloud system & ongoing updates.

Sensors, earphones & power supply are available for purchase separately.

Optional Add-ons

Pre-configured & locked tablet
Remote support end-to-end
Support Hotline

RRP €1,700 (ex. VAT)\(^1\)
RRP €1,850 with tablet (ex. VAT)\(^1\)

Note
1. Pricing for Australian market yet to be confirmed.
New Mente Autism Distribution Partners

• Marketing & distribution partner in Australia
  • Supplies radiological imaging, radiotherapy products & a full range of medical imaging consumable products
  • 20 years experience in bringing premium products, services & support to the Australian healthcare market
  • Strong interest in the system following ASX announcement on clinical trial results

• Exclusive marketing & distribution partner in Saudi Arabia
  • Jeddah based experienced medical device specialist with branches in Riyadh & other regions of Saudi Arabia
  • Represents a wide range of high-tech medical equipment manufactured by companies in the USA & Europe

• Marketing & distribution partner in Germany & Switzerland
  • Gottingen based provider of professional products for biofeedback, neurofeedback & other products for the healthcare & medicine market
  • Provides equipment, systems & consumables from the world’s leading manufacturers, with a focus on delivering independent, competent advice along with fast & uncomplicated service

• Marketing & distribution partner in Greece & Cyprus
  • Athens based distributor for high quality products & innovative technology
  • Focus on products that add value to everyday life, & advance health & wellbeing for users

• Exclusive marketing & distribution partner in Austria
  • Innsbruck based distributor for medical devices & consumables in the fields of urology, neurology & gynaecology
  • Fastest growing neurotechnology distributor in Austria

L to R: at the Malta Research Facility, undertaking training in Italy, Greece, and the Medica International Trade Fair in Düsseldorf
Key Achievements & Next Milestones

Achievements

The Company has made substantial achievements in the space of less than 12 months:

✓ Nov 2016: A$7 million ASX IPO
✓ Dec 2016: First shipments of Mente Autism & appointment of Scientific Advisory Board
✓ Mar – Sep 2017: Secured new Austrian, Greece, German & Swiss, Saudi & Australian distributors, renewed Turkey distributorship
✓ Jun 2017: Australian TGA registration received
✓ Sep 2017: Outstanding preliminary outcomes received from independent US clinical trial

Looking Forward…

We are focussed on continuing to let science do the talking, and bringing Mente Autism to the parents and children who need it

☐ Q4 2017: New UK distributorship
☐ Q4 2017: Completion of US clinical trial
☐ Q1 2018: US FDA submission
☐ Q1 – 2 2018: Mente Autism v 2.0 Improved usability and functionality
☐ Q2 2018: Publication of US trial results in peer-reviewed publications (e.g. Frontiers of Neurology)
☐ 2018: US FDA clearance
☐ Ongoing: additional distributorships and jurisdictions to drive revenue
Contact Details

Neurotech

Company

Wolfgang Storf, Chief Executive Officer
wolfgang.storf@aatrl.com

Neurotech International Ltd
Level 14, 191 St Georges Terrace
Perth Western Australia 6000

Investor / Media Relations

Matthew Wright
matt@nwrcommunications.com.au

NWR Communications
Level 6, 350 Collins St
Melbourne Victoria 3000
Appendices
Case Study: German Market Entry Strategy

- Distributor agreement signed in April 2017 with VDT Psychologie Medizinvertrieb
- Three-step approach to creating structure to develop a successful market in Germany:
  1. Appoint distribution partner (done)
  2. Build medical professional network in collaboration with distribution partner (ongoing)
  3. Create awareness about Mente Autism through participation at symposiums & congresses (ongoing)
- Four medical professionals have received training on Mente Autism – 1 medical doctor, 2 psychiatrists, 1 occupational therapist
- Targeting community of 20 trained medical professionals by end of 2017
- Network will be expanded throughout 2018 as awareness of the product increases
“Mert is a five-year-old boy with ASD who has been using Mente Autism for over three months. Within a few weeks of starting the therapy, we noticed several changes in his communication levels, attention & behaviour.

Mert’s vocabulary has increased, in turn, positively affecting his communication & language skills.

Furthermore, his attention span has increased. Since he started using Mente Autism, Mert is talking a lot more, his reactions to conversations have got better & his behaviour in kindergarten has improved. He also likes puzzles, numbers & his concentration has got better. Mert has also accepted the Mente Autism headband, in fact our son likes the therapy & asks for it every morning without us prompting him.”

- Sendogan Demirtas, Mert’s father, Germany 2017
Update: Italian Market Entry Strategy

• Series of commercial & marketing activities to be organised over the coming months in Italy (Orvieto, Umbria & Corato, Bari), led by distribution partner Promosalute

• A group of 15 children are expected to start using Mente Autism in Q4 2017 in Caserta, under the guidance of a local neuropsychiatrist & the local health authority

• Promosalute will be teaming up with autism group Onlus Diventa Grande, initially introducing Mente Autism to a select group, with the aim to gradually reach out to over 200 member families
  • Ongoing efforts to target similar autism groups in Italy

• Promosalute have engaged a leading marketing company with the aim of creating a highly targeted online marketing exercise
Mente Autism Testimonials

“Since we started using Mente in February 2016, we have noticed a number of behavioral changes in our son. He accepted to use Mente with very few problems, so much so that after some time he started to ask for it when he woke up. This showed us that he sees the therapy as an integral part of his rigid daily routine. We noticed that he started to draw as a means of recreation and with greater attention to descriptive detail that he never showed before. His drawings are nearer and less anxious. In general, the intensity and duration of repetitive actions and moments of estrangement from reality are reduced. He is also responding, in a very positive way, to stimuli that help him to return to normality from his world. As for his behavior, an improved attention span has enabled him to exit his world in a shorter period of time. We have noticed changes in his sleeping habits, in that he is waking up fewer times during the night. Thank you for giving us the opportunity to try the Mente Autism system. The four drawings below are pre- and post- Mente Autism use.”

Fabio and Cristina
Parents of 11-year-old boy ASD
Two-and-a-half months’ usage of August 2016

“We started using Mente Autism six months ago and after only 45 sessions we were shocked that he started to make eye contact with us; to the extent that it became almost normal behavior. This was something we had previously spent nearly two years trying to achieve. The success we achieved in such a short time encouraged us to keep the therapy going. We have noticed other behavioral changes in him. He has started to understand basic orders such as ‘bring the water’, ‘close the door’ and so on. My son not only recognises his name but he turns in the direction where the sound is coming from. This has been an amazing time for us and as a family we are once again hopeful. We are looking forward to using the next generation of Mente Autism and are firm believers in neurofeedback therapy.”

Asra Alhefaz, Parent of 8-year-old child/ ASD/ 45 days’ usage/ Iraq/ August 2016

“After one month of use, our son, Manuel, has accepted the headband. We have seen considerable improvement, in that he is less hyperactive and more relaxed. At school, he often joins in and works with his classmates. He also spends more time in the classroom with them. He has a small area that connects with the classroom where, apart from studying, he takes part in small group activities; a classmate and another student from the other first year class take it in turns to have lunch with him. He appears to accept change with less fear and he is easier to handle during those moments of frustration. In the past month, we have started to use the ABA method at home although we spend fewer hours than is necessary due to teacher issues. However, that said, after a month his carers noticed that it had become easier for him to accept the rules and punishments, such as taking the game away from him if he does not obey a rule. The carers also noticed that in a short period of time he is capable of formulating requests. He has started to copy pictures (a kite, cloud) and is better at colouring. During a school outing, his teacher was surprised and deeply touched when she saw him taking part in activities with his classmates. Birthday parties are still a challenge for him to interact with his friends; the attention paid to smart phones and other novelties still causes him to somewhat withdraw from the group.”

Cristina, Parent of 7-year-old boy ASD/ 45 days’ usage/ Italy/ August 2016
Disclaimer

This presentation contains forward looking statements that involve risks and uncertainties. These forward looking statements are not guarantees of Neurotech’s future performance and involved a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements.

This presentation only contains information required for a preliminary evaluation of the company and in particular only discloses information by way of summary within the knowledge of the company and its directors. An investor should seek its own independent professional advice in relation to the technical, financial, taxation, legal and commercial matters relating to any investment in Neurotech.

Other than to the extent required by law (and only to that extent) the company and its officers, employees and professional advisers make no representation, guarantee or warranty (express or implied) as to, and assume no responsibility or liability for, the contents of this presentation.